Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignancy after transplantation.

Joseph F Buell1, Thomas G Gross, E Steve Woodle

  • 1Israel Penn International Transplant Tumor Registry, University of Cincinnati, Cincinnati, OH 45267-0558, USA. joseph.buell@uc.edu

Transplantation
|October 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Not all reference samples are equal in single-cell transcriptomics of human kidney tissue.

JCI insight·2026
Same author

Deep profiling of lupus nephritis kidneys reveals dynamic changes in myeloid cells associated with disease progression.

Annals of the rheumatic diseases·2026
Same author

Risk factor analysis of 115 children and adolescents with primary mediastinal B-cell lymphoma treated with DA-EPOCH-R.

Blood advances·2026
Same author

A population-scale atlas of blood and tissue in lupus nephritis.

bioRxiv : the preprint server for biology·2026
Same author

Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CO-STIMULATORY BLOCKADE PREVENTS INTRAGRAFT ACCRUAL OF CLASS-SWITCHED, ACTIVATED B CELLS DESPITE FAILING TO PREVENT T-CELL MEDIATED REJECTION.

bioRxiv : the preprint server for biology·2025
Same journal

Simultaneous Liver-kidney Versus Liver Transplantation Categorized by Pretransplant eGFR: Impact of the 2017 OPTN Policy.

Transplantation·2026
Same journal

Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

Transplantation·2026
Same journal

People in Transplantation: Professor Nadey Hakim, MD, PhD, FRCS, FRCSGlas (Hon), FACS, President-Elect of The Transplantation Society.

Transplantation·2026
Same journal

IL-1 Receptor Blockade Modulates Inflammation During Sequential Perfusion in Ex Vivo Porcine Kidneys.

Transplantation·2026
Same journal

Regulatory T Cells Allosensitized Under the Blockade of CD80/CD86-CD28 Costimulation Prolonged Islet Allograft Survival.

Transplantation·2026
Same journal

Desensitization With Tocilizumab and IVIg: A Prospective Controlled Cohort Study in a Predominantly Black American Population.

Transplantation·2026
See all related articles

Post-transplant cancer is a growing concern, surpassing cardiovascular issues as a leading cause of death. Understanding and minimizing cancer risks in transplant recipients is crucial for improving long-term survival.

Area of Science:

  • Transplant medicine
  • Oncology
  • Immunology

Background:

  • Post-transplant malignancy is an increasing cause of mortality in organ transplant recipients.
  • Cancer is projected to become the leading cause of death in transplant patients within two decades.
  • Understanding the multifactorial etiology of post-transplant cancers is essential.

Purpose of the Study:

  • To review the pathobiology of post-transplant malignancy.
  • To discuss strategies for minimizing cancer risks in transplant recipients.
  • To evaluate the role of immunosuppressive agents in post-transplant cancer development.

Main Methods:

  • Literature review of post-transplant malignancy.
  • Analysis of immunosuppressive agents and their link to cancer.

Related Experiment Videos

  • Discussion of viral-related malignancies in transplant patients.

    • Main Results:

    • Post-transplant malignancy is multifactorial, involving impaired immunosurveillance and depressed antiviral immunity.
    • Common post-transplant cancers are often viral-related.
    • Calcineurin inhibitors and azathioprine are linked to post-transplant malignancies, while newer agents like mycophenolate mofetil and sirolimus may have antitumor properties.

    Conclusions:

    • Minimizing cancer risks in transplant recipients requires understanding complex pathobiology.
    • Newer immunosuppressive agents may offer a safer profile regarding malignancy risk.
    • Long-term data are needed to confirm the impact of current immunosuppressive regimens on post-transplant cancer mortality.